Her RLS Drug Is Working Less and Spreading Further — That’s Not the Disease Getting Worse
Her symptoms are worse, and spreading to her arms — the intuitive read is that her restless legs syndrome is simply progressing. It isn’t. The drug treating it is very likely the thing making it worse.
L.B., a 63-year-old woman, retired four years ago from a long career as a school administrator, work she describes as having genuinely loved despite the stress of it, and now spends much of her time volunteering at her grandchildren’s elementary school and tending a large vegetable garden she finally has time for. She has taken pramipexole for restless legs syndrome for just over four years, started originally at a low dose that controlled her evening leg discomfort well for the first two to three years — a period she remembers as genuinely restoring her sleep after several miserable months before diagnosis. She lives with her husband, has no other major medical conditions besides osteoarthritis in one knee managed conservatively with occasional acetaminophen, and her ferritin was checked at the time of her original diagnosis and came back within normal range, with no history of anemia at any point.
Over the past eight months, her symptoms have changed in a way that alarmed her enough to schedule this visit outside her usual follow-up interval: her restless, uncomfortable sensations now begin in the mid-afternoon rather than only in the evening, sometimes while she’s still gardening, and have started involving her arms in addition to her legs for the first time since her diagnosis. Her physician had already increased her pramipexole dose twice in response over that period, each time with only brief relief lasting a few weeks before the same pattern crept back, now arriving earlier in the day and spreading further than before. She came in today assuming, reasonably enough from her own experience, that her RLS is simply getting worse with age, and wondering aloud whether yet another dose increase is the answer, or whether she should brace herself for this being how it is now.
In clinic, after the second dose increase failed to hold
What she’s describing is a textbook presentation of dopamine-agonist augmentation, not disease progression, and I think that distinction has to be named clearly before we do anything else. Augmentation is a well-documented, paradoxical worsening of RLS symptoms caused by long-term dopaminergic therapy itself — earlier symptom onset, spread to previously unaffected limbs, and a pattern of brief relief followed by recurrence after each dose increase are its classic hallmarks, not signs the underlying disease has become more severe.
The 2025 AASM clinical practice guideline moved decisively away from dopamine agonists as first-line therapy specifically because of this risk, and her case is close to a worked example of why.
I’d add the mechanistic piece that makes the next step clear, and it changes what her ferritin status actually means here. Low iron is a well-documented risk factor for both RLS itself and for augmentation specifically, and the IRLSSG’s iron guideline sets a treatment threshold of ferritin above 75 ng/mL for RLS — substantially higher than the threshold used for ordinary iron-deficiency anemia. Her ferritin was normal by general standards four years ago, but it was never checked against this RLS-specific threshold, and it hasn’t been rechecked since.
The critical point, and the reason another dose increase would very likely make things worse rather than better: increasing the dopamine agonist dose in a patient already augmenting doesn’t just fail to help — it accelerates the same paradoxical worsening pattern she’s already experiencing.
Agreed without real disagreement: iron studies rechecked against the RLS-specific threshold, pramipexole cross-tapered down rather than increased, and gabapentin enacarbil started as the replacement first-line agent, consistent with the 2025 AASM guideline shift.
Both voices converged directly on the same diagnosis and plan — the pharmacologist’s iron-threshold and mechanism point built on, rather than contested, the sleep physician’s augmentation diagnosis, and L.B. was told plainly that her worsening symptoms reflected the treatment, not her disease progressing.